| - Industry | - Sector | Mr. Gregory Fenton C.F.A. CEO | XFRA Exchange | CA6517281078 ISIN |
| Canada Country | 24 Employees | - Last Dividend | 15 Aug 2022 Last Split | - IPO Date |
Zentek Ltd., a Canadian company, specializes in the exploration and development of graphene and its related nanomaterials. The company's activities span various applications of graphene technology, including the creation of antimicrobial coatings, development of pharmaceutical products, and enhancement of personal protective equipment. Zentek's commitment to innovation is also evident in its efforts to synthesize graphene and graphene oxide. Moreover, the company is the sole owner of the Albany graphite project situated in Northern Ontario, Canada, highlighting its integrated approach to graphene research and development. Originally named ZEN Graphene Solutions Ltd., it underwent a rebranding to Zentek Ltd. in October 2021, signaling a broadened focus or strategic shift. Founded in 2008 and headquartered in Guelph, Canada, Zentek positions itself at the forefront of nanomaterial technology, addressing a wide range of industrial and healthcare challenges.
This graphene-based antimicrobial coating developed by Zentek is one of its flagship products. Recognized for its effectiveness, the ZenGUARD brand encompasses a variety of applications, including healthcare settings and consumer products, by providing an extra layer of protection against microbial growth.
Zentek leverages its graphene technology to enhance the protective capabilities of surgical masks and other personal protective equipment. These products are designed to offer superior protection against pathogens, benefiting healthcare professionals and the general public alike.
The incorporation of graphene technology into HVAC filters represents another innovative application by Zentek. These filters offer improved air quality and efficiency, contributing to healthier indoor environments in residential, commercial, and industrial settings.
Zentek is also developing graphene-based diagnostic tests aimed at rapid detection of various diseases at the point of care. These tests are designed to be quick, accurate, and easily administrable, facilitating timely diagnosis and treatment.
Exploring the potential of graphene-based compounds, Zentek is involved in the development of pharmaceutical products. These products aim to harness the unique properties of graphene to enhance drug delivery and efficacy, potentially revolutionizing treatment approaches for various conditions.
At the core of Zentek's R&D efforts are its graphene oxide and graphene synthesis processes. These processes are crucial for producing high-quality graphene materials, serving as a foundation for the company's wide-ranging product portfolio.
Zentek's ownership of the Albany graphite project underscores its commitment to securing a reliable source of raw materials necessary for graphene production. Located in Northern Ontario, Canada, this project is pivotal in supporting the company's ambitious R&D initiatives.